Value & Access

Many of the 121.5 million Americans living with cardiovascular disease face barriers to getting the treatment that is right for them. The National Forum is engaging diverse stakeholders in a transformative, consensus-building initiative to overcome the barriers. Together, we are accelerating collaboration, breaking the stalemate and improving access to evidence-based care.

What do Value & Access Really Mean?

This National Forum landscape report reveals how patients, providers, payers, public health and industry view the value of therapies and what access means to them.

Consensus Goal

Enhance health and well-being by supporting people’s access to evidence-based care that is appropriate for them by:

  • Identifying evidence-based strategies for determining appropriateness of care
  • Supporting the implementation of evidence-based care that aligns incentives for patients, providers, payers, other stakeholders

The Steering Committee will share research, facts, best practices and policies to advance the consensus goal through its Action Agenda.

Action Agenda

Understand Best Practices on Payer/Purchaser Coverage Decisions

Highlight a way for all stakeholders to communicate, share evidence, best practices & identify areas for improvement


Patient Engagement Strategies

Identify effective and scalable shared-decision making tools and models

Patient Adherence

Identify and endorse or highlight models, research, tools and resources

Shift Spend From Low- to High-Value Care

Identify & support effective leverage points already underway that meet stakeholder needs

Value & Access Clearinghouse

Stakeholder Resources - Click on the Icons Below For Relevant Resources

Value & Access Initiative Resources

Through the Value & Access initiative, the following resources have been developed.

National Forum landscape report reveals how patients, providers, payers, public health and industry view the value of therapies and what access means to them.





SHARED Decision Making Tool for Patients & Providers – Worksheets designed for patients and providers to use in role modeling conversation on discussing  FH (familial hypercholesterolemia) and Statin-Related Side Effects, and Atheriosclerotic Cardiovascular Disease (ASCVD) treatment options, concerns, preferences, and goals created in collaboration with the FH Foundation, National Lipid Association, and American Pharmacists Association Foundation.








Best Practices for Pharmacy & Therapeutics (P&T) Committees

A checklist modeling processes for P&T Committees to consider when managing the formulary system in making equitable coverage decisions, focusing on evidence-based processes to select and promote treatments offering the best therapeutic outcomes, while minimizing potential risks and costs to patients.

Steering Committee Members

The steering committee includes a broad range of experts representing public health, patients, providers, payers, and pharma/biotech.

Michael Cropp, MD, MBA

Title Steering Committee Chair

Positions held
  • President & CEO, Independent Health


Andrea Baer

Positions held
  • Executive Director, Mended Hearts

Madeleine Konig, MPH

Positions held
  • Director, Value in Healthcare Initiative, American Heart Association (AHA)

Amy Friedrich-Karnik

Positions held
  • Director, Public Policy, WomenHeart

Sara Traigle van Geertruyden

Positions held
  • Executive Director, Partnership to Improve Patient Care



Positions held
  • Senior Medical Director, Cigna Healthcare
  • Clinical Performance and Quality National Medical Director Cardiology and Cardiovascular Diseases,

Jim Ballenger, MBA

Positions held
  • Principal, BallengeRx Consulting

Michael Cropp, MD, MBA

Positions held
  • President and Chief Executive Officer, Independent Health

Michael Thompson, FSA

Positions held
  • President and CEO, National Alliance of Healthcare Purchaser Coalitions



Positions held
  • Immediate Past President, American Society for Preventive Cardiology (ASPC)

Benjamin M. Bluml, RPh

Positions held
  • Senior Vice President Research and Innovation, American Pharmacists Association (APhA) Foundation

Brian Hart, JD

Positions held
  • Executive Director, National Lipid Association

Sue Koob, MPA

Positions held
  • CEO, Preventive Cardiovascular Nurses Association (PCNA)

Karyn Lockshine, CAE

Positions held
  • Executive Director, American Association of Heart Failure Nurses

Cassandra McCullough, MBA

Positions held
  • CEO/Executive Director, Association of Black Cardiologists

J. Brendan Mullen

Positions held
  • Executive Vice President, American College of Cardiology

Jennifer G. Robinson, MD, MPH

Positions held
  • Professor Departments of Epidemiology & Medicine,
  • Director Prevention Intervention Center, University of Iowa

Joyce Ross, MSN, CRNP, CS, CLS, FNLA

Positions held
  • President 2016-2017, National Lipid Association

Public Health

A. Mark Fendrick, MD

Positions held
  • Director Center for Value-Based Insurance Design (V-BID), University of Michigan

Miriam Pitanian, MPH

Positions held
  • National Association of Chronic Disease Directors

Marcus Plescia, MD, MPH

Positions held
  • Chief Medical Officer , Association of State and Territorial Health Officials (ASTHO)

Fortunato “Fred” Senatore, MD, PhD, FACC 

Positions held
  • Medical Officer, Division of Cardiovascular and Renal Products, Center for Drug Evaluation and Research, Food and Drug Administration


Kimberly Westrich, MA

Positions held
  • Vice President for Health Services Research, National Pharmaceutical Council (NPC)

This initiative is made possible through support from the following:

Founding Sponsor